Table 5. Results of indication biopsies in KTRs with AMR and TCMR based on the Banff 2013 classification system.
| Variables | No. | DSA status | Stage | g | ptc | i | t | v | ci | ct | cv | ah | cg | mm | c4d in ptc |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMR | 1 | De novo anti-HLA Ab (+) DSA (+) | II | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 |
| 2 | De novo anti-HLA Ab (+) DSA (+) | II | 3 | 2 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | 0 | 0 | 2 | |
| 3 | De novo anti-HLA Ab (+) DSA (+) | II | 3 | 3 | 3 | 3 | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 3 | |
| TCMR | 1 | De novo anti-HLA Ab (+) DSA (+) | III | 1 | 0 | 1 | 1 | 3 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| 2 | De novo anti-HLA Ab (+) DSA (−) | IIA | 0 | 0 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |
| 3 | Control | IIA | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |
| 4 | Control | IB | 0 | 1 | 2 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |
| 5 | Control | IA | 0 | 1 | 2 | 2 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 1 | |
| 6 | Control | IA | 0 | 1 | 2 | 2 | 0 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | |
| 7 | Control | IA | 0 | 0 | 2 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| 8 | Control | IA | 0 | 0 | 2 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 2 |
Banff scoring categories: g = glomerulitis, ptc = peritubular capillary inflammation, I = interstitial inflammation, t = tubulitis, v = vascular inflammation, ci = interstitial fibrosis, ct = tubular atrophy, cv = arterial fibrointimal thickening, ah = arteriolar hyaline thickening, cg = transplant glomerulopathy, mm = mesangial matrix increase.
KTRs = kidney transplant recipients, AMR = antibody-mediated rejection, TCMR = T-cell medicated rejection, DSA = donor-specific anti-human leukocyte antigens antibodies, anti-HLA Ab = anti-human leukocyte antigens antibodies.